Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Characteristics of patients treated with CyberKnife for pelvic re-irradiation.

From: Robotic image-guided reirradiation of lateral pelvic recurrences: preliminary results

  Number (%) Mean (range) Comments
Patients 16   
   Sex (M/F) 6 (37%)/10 (63%)   
   Age* 55 (34 - 70 y.o.)  
Primary disease    
Anal canal 6 (38%)   
Cervix 4 (25%)   
Uterus 1 (6%)   
Rectum 4 (25%)   
Bladder 1 (6%)   
Primary treatment    
Surgery 9 (56%)   
Chemotherapy 13 (81%)   9 concomitant; 4 adjuvant
Radiotherapy 14 (87%)   
   Dose*   45 Gy (20-75 Gy)  
   Eq D2*    
Early side effects (α/β = 3 Gy)   45 Gy (33-58 Gy)  
Late side effects (α/β = 10 Gy)   72 Gy (53-96 Gy)  
Treatment of the recurrence    
Surgery 6 (38%)   
Chemotherapy 8 (50%)   
Radiotherapy 3 (19%)   
   Dose*   53.7 Gy (36-66 Gy)  
   Eq D2*    
Early side effects (α/β = 3 Gy)   65 Gy (45-66 Gy)  
Late side effects (α/β = 10 Gy)   106 Gy (72-110 Gy)  
  1. * Median value